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IntroductionAutism spectrum disorders (ASDs) affect ~1% of the popu-
lation and are characterized by impairments in social
interaction and communication, as well as by repetitive
and restricted behaviors. ASDs includemild to severe levels
of impairment—cognitive function ranges from above
average to intellectual disability (ID)—and are often
accompanied by seizures and other medical problems.
There is a ~4:1 male-to-female gender ratio in ASD.
ASDs are highly heritable,1 and genomic studies have
revealed that a substantial proportion of ASD risk resides
in high-impact rare variation, ranging from chromosome
abnormalities and copy-number variation (CNV)2–6 to
single-nucleotide variation (SNV).7–11 These studies have
highlighted a striking degree of genetic heterogeneity,
implicating both de novo germline mutation and rare in-
herited ASD variation distributed across numerous genes.
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some of them have proven to alter high-risk genes (e.g.,
NRXN112 [MIM 600565]). De novo or transmitted CNVs,
such as 15q11.2–q13 duplications of the affected region
in Prader-Willi syndrome (PWS [MIM 176270]) and Angel-
man syndrome (AS [MIM 105830]), 16p11.2 deletion
(MIM 611913), 16p11.2 duplication (MIM 614671), and
X-linked deletions including the PTCHD1-PTCHD1AS
locus (MIM 300828), have also been found to contribute
to risk.6,13,14 Exome and whole-genome sequencing
studies have estimated at least another ~6% contribution
to ASD7–10,15 and an additional 5% conferred by rare
inherited recessive or X-linked loss-of-function (LoF)
SNVs.11,16 A genetic overlap between ASD and other
neuropsychiatric conditions has also been increasingly
recognized.
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might still perturb connected biological pathways.17
Although numerous ASD-associated loci have been recog-
nized to date,18 they only account for a small fraction of
the overall estimated heritability, consistent with predic-
tions that there might be ~1,000 loci underlying ASD19
and that many associated genes and risk variants remain
to be identified.
Here, we have assessed the impact of de novo and in-
herited rare CNV in 2,446 ASD individuals and their
parents from the Autism Genome Project (AGP), along
with 2,640 unrelated controls, by applying a series of
approaches to characterize candidate ASD-associated genes
disrupted by CNVs and to identify the biological relation-
ships and common pathways they share. Using evidence
from multiple sources, we were able to directly implicate
numerous dosage-sensitive genes as risk factors and pro-
vide insights into different but related mechanisms under-
lying ASD.Subjects and Methods
ASD Samples
The sampleswere collected as part of theAGP, an international con-
sortium with over 50 sites in North America and Europe. The first
phase of theAGP involved examining genetic linkage and chromo-
somal rearrangements in 1,168 families with at least two ASD-
affected individuals.5 In the second phase, we genotyped simplex
and multiplex families by using high-resolution microarrays to
examine the contribution of rare CNVs and common SNPs to
ASD. The second phase was divided in two stages; the results of
stage 1, involving the first half of the families, were published in
2010.6,20 In stage 2, we genotyped the remaining families (n ¼
1,604) for a total of over 2,845 families and performed genome-
wide CNV (this study) and association studies.21 Informed consent
was obtained from all participants, and all procedures followed
were in accordance with the ethical standards on human experi-
mentation of the participating sites. The AGP sample set is a collec-
tion of families comprising an affected proband and twoparents, as
previously described in Pinto et al.6 and Anney et al.20,21 Many of
the subjects at the recruiting siteswere tested for fragileX syndrome
(FXS [MIM300624]) andassessed forchromosomal rearrangements
with karyotype, fluorescence in situ hybridization, or multiplex-
ligation-dependent probe amplification (MLPA); subjects with
known karyotypic abnormalities, FXS, or other genetic disorders
were typically excluded. The main analyses presented here were
restricted to subjects of European ancestry.21 All diagnostic, clin-
ical, and cognitive assessments were carried out at each contrib-
uting site. All data were gathered at a central coordination site for
standardization of data formatting and data quality assurance.Autism Classification
Affected AGP participants were classified according to the Autism
Diagnostic Observation Schedule (ADOS)22 and the Autism Diag-
nostic Interview, Revised (ADI-R).23 The ADOS is a semistructured,
clinically administered instrument for assessing and diagnosing
ASD. The ADI-R is a structured clinical interview conducted with
the parents or caregivers; spectrum classification on the ADI-R
was based on Risi et al.24 The AGP strict and spectrum classifications
are based on both instruments (Table S1A, available online). ToThe Ammeet criteria for strict autism, affected individuals must have an
autism classification on both measures, whereas for the spectrum
classification, individuals must meet the autism spectrum criteria
on both measures or meet criteria for autism on one measure if
the other measure was not available or not administered. The
mean age of ADI-R assessment was 8 years.
Simplex and Multiplex Classification
Family type was classified as simplex, multiplex, or unknown. Sim-
plex families had one known affected individual among the first- to
third-degree relatives (cousins only) and includedaffectedmonozy-
gotic twins. Multiplex families had at least two first- to third-degree
relatives (cousins only) with a validated, clinical ASD diagnosis. All
other situations, including instances where a family history of
autism was not assessed explicitly, were coded as unknown.
Developmental Impairment
Cognitive functioning and adaptive function were measured with
an appropriate standardized cognitive-testing instrument and the
Vineland Adaptive Behavior Scale (VABS),25 respectively. To maxi-
mize the available data, we created a developmental-impairment
variable by using a hierarchical combination of scores on full-
scale, performance, and verbal IQmeasures and the VABS compos-
ite score. A cutoff of 70 was applied on all measures; subjects who
could not complete an IQ assessment because of low functioning
or behavior were assigned to the ‘‘low’’ category. In the hierarchy,
full-scale IQ (followed by performance IQ, verbal IQ, and finally
the VABS composite score) was the preferred measure. For
example, a subject with a full-scale IQ < 70 but a performance
IQ R 70 was considered positive for developmental impairment.
Additionally, subjects missing all IQ information with a ‘‘low’’
VABS composite score were also assigned to the developmental-
impairment category.
Control Subjects
Unrelated control subjects were assembled from three studies in
which individuals had no obvious psychiatric history: the Study
of Addiction Genetics and Environment (SAGE),26 the Ontario
Colorectal Cancer Case-Control Study,27,28 and Health, Aging,
and Body Composition (HABC) (Table S1B).29 Samples were geno-
typed on the same array platforms (Illumina 1M single or duo
arrays) as those of ASD subjects and parents and were analyzed
with the same quality-control (QC) procedures and CNV analysis
pipeline. The control data set used in the primary CNV analysis
was composed of 2,640 control individuals of European ancestry
(1,241 males and 1,399 females) who passed QC (Table S1B).
Secondary analyses included 1,843 subjects from other ancestries
(SAGE and HABC non-European control individuals), giving a
total of 4,768 control subjects of all ancestries.
Data Analysis
We performed genotyping and data cleaning, including SNP
and intensity QC for CNV detection, as described previously6 to
ensure that CNV ascertainment was consistent among affected
subjects, parents, and control subjects (see Table S1B for detailed
QC steps). Samples not meeting our quality thresholds were
excluded.
CNVAnalysis
CNVs were detected with our analytical pipeline of Illumina 1M
arrays (v.1 and v.3)6,30 and analyzed for case-control differenceserican Journal of Human Genetics 94, 677–694, May 1, 2014 679
in burden with PLINK v.1.0730, R stats, and custom scripts. The
p values associated with odds ratios (ORs) were calculated with
Fisher’s exact test. Rare de novo CNVs, clinically relevant CNVs,
and other selected rare CNVs were validated by at least one
method (quantitative PCR, MLPA, and/or long-range PCR). Table
S4 shows all validated de novo CNVs. A list of CNV calls passing
QC in affected subjects, including all experimentally validated
CNVs, is available in Tables S17A, S17B, and S17C.
Secondary analyses included comparisons of CNV number,
length, and intersected gene number between our 102 de novo
CNVs identified in affected subjects and the 76 de novo CNVs in
control subjects of two published data sets: (1) 17 de novo CNVs
identified in 15 unaffected siblings from 872 families with a single
ASD-affected offspring and an unaffected sibling from the Simons
Simplex Collection4 and (2) 59 de novoCNVs detected in 57 out of
2,623 Icelandic control trios.31
The clinical relevance of CNVs was interpreted according to the
American College of Medical Genetics guidelines32 irrespective of
the subjects’ affected status, and CNVs were classified as patho-
genic, uncertain, or benign. Pathogenic CNVs are documented
as clinically significant in multiple peer-reviewed publications
and databases (e.g., OMIM and GeneReviews), even if the pene-
trance and the expressivity might be variable.Gene Lists
In order to perform burden analyses, we compiled a series of lists:
(1) Genes and loci implicated causally in ASD (updated from
Betancur),18 all of which have also been implicated in
ID, as well as genes and loci implicated in ID, but not yet
in ASD (Tables S6A–S6D). Note that the list of genes
and loci involved in ASD was updated independently of
the data from AGP stage 1;6 thus, genes and loci were
included only if there was independent evidence from
other studies.
(2) Highly-brain-expressed genes defined by a log(RPKM [reads
per kb per million reads]) > 4.5 by the BrainSpan resource
(n ¼ 5,610 genes).
(3) Functionally characterized control genes not expressed in
the brain (log(RPKM) < 1; n ¼ 5,410 genes).
(4) Postsynaptic density (PSD) genes.33
(5) Genes found to interact with fragile X mental retardation
protein (FMRP).34
(6) Genes associated with neurological phenotypes compiled
from the Human PhenotypeOntology (HPO) andMamma-
lian Phenotype Ontology (MPO).
(7) Genes grouped by their probability of haploinsufficiency
(pHI)35 into three subgroups: pHI> 0.15 (n¼ 8,862 genes),
pHI > 0.35 (n ¼ 4,136 genes), and pHI > 0.55 (n ¼ 2,214
genes).One-Gene- and Multiple-Gene-Hit Burden Analysis
One-gene-hit burden analyses were performed with Fisher’s exact
test. When considering the possibility that multiple genes within
a CNV event or across events in the same subject act in concert to
increase risk (i.e., multiple-gene-hit burden), we fit a series of logit
models to the data. For the logit model, which is a special case of
generalized linear model, log odds of case status (logit) was fit to
predictor variables, namely the number of brain-expressed genes
(BrainSpan) covered by the CNV and the level of gene expression.
To analyze the expression data, we transformed the normalized680 The American Journal of Human Genetics 94, 677–694, May 1, 2RPKM value of each gene in the neocortex to log(1þRPKM). All
analyses were performed in the statistical package R with the func-
tion ‘‘glm’’ and the logit link.
Functional Enrichment and Network Analyses
Functional-enrichment association tests and pathway and net-
work analyses were performedwith custom scripts,6 Bioconductor,
NETBAG,36 and DAPPLE.37Results
Excess Genome-wide Burden of Rare and De Novo
Genic CNVs
To explore the contribution of CNV to ASD, we expanded
our previous study (stage 1)6 with an additional 1,604 fam-
ilies (stage 2), bringing the total to 9,050 individuals from
2,845 ASD-affected families.We used an analytical pipeline
of Illumina 1M arrays6,30 to detect rare CNV in families and
applied a series of QC filters, including validation of all
de novo events by at least one method (Tables S1A–S1C).
In total, 1,359 stage 2 families passed QC, and 2,446
families were used in the combined analyses of both stages
(Tables S2A and S2B). Of these, 2,147 families were Euro-
pean, and 299 were of other ancestries.21 We used the
same pipeline to analyze 2,640 control individuals of
European ancestry26,27,29 who were genotyped with the
same array platforms. Ancestry was inferred by analysis
of SNP genotype data (Table S1B). The rate, size, and num-
ber of genes affected by rare (<1% frequency) CNVs were
assessed. Consistent with our previous data, we observed
that compared to control subjects, affected subjects had
an increased burden in the number of genes affected by
rare CNVs (1.41-fold increase, empirical p ¼ 1 3 105;
Table 1). This enrichment was apparent for both deletions
and duplications and remained after we controlled for
potential case-control differences (Table 1). Similar find-
ings were obtained when each stage was considered sepa-
rately (Tables S3A–S3C).
Array- and exome-based studies have revealed a substan-
tial contribution of de novo variation to ASD risk,19
prompting us to assess this further. After screening 2,096
trios (of all ancestries), we found 102 rare de novo CNVs
in 99 affected subjects (three of whom had two events;
Table S4). Overall, 4.7% of trios had at least one de novo
CNV, whereas control subjects had a frequency of 1%–
2%.4,31,38 The average length of de novo events in our
affected subjects (1.17 Mb) was larger than that of de
novo CNVs in unaffected siblings from the Simons Sim-
plex Collection (0.67 Mb, p ¼ 0.01)4 and in control trios
(0.55 Mb, p ¼ 0.01).31 The average size of de novo CNVs
was also larger than the size of all rare CNVs in our affected
(188 kb) and control (159 kb) subjects. De novo CNVs
affected 3.8-fold more genes in affected subjects than in
control subjects4,31 (2.6-fold for deletions and 6.1-fold for
duplications). Even after controlling for the difference in
CNV size by proportionally scaling the number of inter-
sected genes in each group, we observed a 1.77-fold014
Table 1. Genome-wide Burden of Genes Intersected by Rare CNVs in a Combined Sample of 2,147 European ASD Affected Subjects and
2,640 European Control Subjects
Type Group Size
No. of Rare
Genic CNVs
No. of Genes Intersected
by Rare CNVs
Baseline Gene
Rate (Control)a
Case-Control
Gene Ratio pcorr
b
All all 6,859 6,745 3.55 1.41 0.00001*
Deletions all 2,946 2,804 1.23 1.40 0.00049*
Duplications all 3,913 5,217 2.32 1.41 0.00001*
All 30–500 kb 6,307 5,163 2.89 1.07 0.03628*
>500 kb 552 2,491 0.66 2.88 0.00001*
>1 Mb 187 1,337 0.26 4.48 0.00001*
Deletions 30–500 kb 2,795 2,014 1.07 1.07 0.20110
>500 kb 151 947 0.16 3.60 0.00051*
>1 Mb 63 647 0.08 4.58 0.02289*
Duplications 30–500 kb 3,512 3,934 1.83 1.08 0.03750*
>500 kb 401 1,896 0.50 2.64 0.00026*
>1 Mb 124 890 0.18 4.43 0.00036*
Rare CNVs in samples of European ancestry were defined asR30 kb in size and present in the total sample set at a frequency< 1%. Gene coordinates were defined
by the RefSeq boundaries plus a 10 kb region on either side. All genomic analyses used UCSC Genome Browser hg18. *Significant differences (p % 0.05) are
indicated.
aThe baseline gene rate (control) is defined as the average number of genes intersected by CNVs per control subject.
bGenome-wide p values were estimated in 100,000 permutations (one sided) and additionally corrected (pcorr) for global case-control differences in CNV rate and
size. Analyses were further stratified according to CNV type (deletions or duplications) and size.difference (1.2-fold for deletions and 2.8-fold for duplica-
tions, p ¼ 0.02). Furthermore, de novo CNVs in simplex
families intersected 4.0-fold more genes than did CNVs
in controls4,31 (1.8-fold after size correction, p ¼ 0.01).
There were no significant differences between subjects
from simplex families and those from multiplex families
in the frequency (5% and 4.2%, respectively) or gene con-
tent (n ¼ 18.7 and 18.8, respectively) of de novo CNVs.
Similarly, no significant difference was found between
males and females in the size (1.17 and 1.2 Mb, respec-
tively) or gene content (n ¼ 18 and 17.3, respectively) of
de novoCNVs. For 85 of 102 de novo events, it was possible
to determine the parent of origin, and roughly equal
numbers of events originated on the paternal allele (n ¼
45) and the maternal allele (n ¼ 40) (Tables S5A–S5H).
Taken together, our data indicate that there is an increased
burden of de novo events in ASD-affected subjects. The
clinical relevance of de novo CNVs in ASD is confirmed
by the fact that among 102 such events identified, half
(n ¼ 46) are considered etiologically relevant, including
40 loci known to be involved in ASD and ID (see below).
We replicated previous observations, such as a de novo
deletion intersecting PTCHD1AS in a male (adding to the
evidence that both PTCHD1 and PTCHD1AS contribute to
ASD risk14) and de novo events involving the miRNA
miR137 (MIM614304) in 1p21.2–p21.3 in two subjects.Mi-
crodeletions of miR137 have been reported in ASD,39 ID,40
and schizophrenia.41 Examples of ASD candidate genes
identified by small de novo CNVs include SETD5, DTNA
(MIM 601239), and LSAMP (MIM 603241) (Supplemental
Data section ‘‘HighlightedGenes,’’ Figures S9, S10, andS14).The AmCNV Burden in Autosomal-Dominant or X-Linked
Genes and Loci Implicated in ASD and/or ID
At least 124 genes and 55 genomic loci have been impli-
cated in ASD to date (Tables S6A and S6B; updated from
Betancur18), all of which have also been implicated in ID.
In addition, we compiled a list of genes and loci that
have been implicated in ID, but not yet in ASD (Tables
S6C–S6D). When we analyzed samples of inferred
European ancestry, we found that 4% (87/2,147) of ASD-
affected subjects had CNVs overlapping autosomal-domi-
nant or X-linked genes and loci implicated in ASD and/or
ID; this percentage was significantly higher than that in
controls (OR ¼ 4.09, 95% confidence interval [CI] ¼
2.64–6.32, p ¼ 5.7 3 1012; Figure 1A). We further classi-
fied these events into pathogenic, uncertain, or benign
according to the American College of Medical Genetics
guidelines.32 Pathogenic (or clinically significant) CNVs
were identified in 2.8% (60/2,147) of affected subjects
(OR ¼ 12.62, 95% CI ¼ 5.44–29.27, p ¼ 2.74 3 1015),
and pathogenic deletions showed a striking estimated OR
of 23.13 (95% CI ¼ 5.57–96.08, p ¼ 2.6 3 1011;
Figure 1B). Furthermore, the enrichment of pathogenic
CNVs overlapping genes involved in ASD and/or ID was
independently observed when the data were broken
down by stages: 2.6% (25/979) of affected subjects in stage
1 (OR ¼ 7.61, p ¼ 1.22 3 105) carried pathogenic CNVs,
whereas 3.0% (35/1,168) in stage 2 (OR ¼ 6.47, p ¼
2.89 3 107) carried pathogenic CNVs. Some of these
CNVs (e.g., NRXN1 deletion, 1q21 duplications [MIM
612475], and 16p11.2 duplications) were seen in a small
fraction of control subjects, consistent with their variableerican Journal of Human Genetics 94, 677–694, May 1, 2014 681
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Figure 1. CNV Burden in Genes and Loci Implicated in ASD
and/or ID
CNV data from 2,147 European affected subjects and 2,640 Euro-
pean control subjects were analyzed for overlap with genes and
loci implicated in ASD and/or ID (results including non-European
affected and control subjects are shown in Figure S1). Only CNVs
affecting autosomal-dominant and X-linked dominant genes or
loci in both genders (132 genes, 56 loci), as well as X-linked reces-
sive genes or loci in males (52 genes, 2 loci), were considered (‘‘all
CNV’’). ExonicR30 kb CNVs affecting an ASD- and/or ID-associ-
682 The American Journal of Human Genetics 94, 677–694, May 1, 2expressivity and/or incomplete penetrance. Among the
affected subjects with pathogenic CNVs, 63% (38/60) car-
ried de novo events (Figure 1C), including two subjects
with two pathogenic events each.
When we further considered affected subjects of all
ancestries (n ¼ 2,446) and included chromosome abnor-
malities (>7.5 Mb), select large rare de novo events, and
select experimentally validated smaller CNVs (<30 kb),
we identified pathogenic CNVs in ~3.3% of individuals
with unexplained ASD (84 pathogenic events in 82/2,446
subjects; Figures 2A and S1A–S1C; Tables S7A and S7B).
This most likely represents an underestimate of the true
etiologic yield, given that many of the subjects were
assessed with clinical diagnostic methods and excluded
if positive; similarly, those individuals with known con-
genital malformations or dysmorphic features were not
enrolled. Interestingly, 83% (64/77 [5 without informa-
tion]) of carriers of pathogenic CNVs were nonsyndromic
(i.e., ASD without reported accompanying physical or
neurological abnormalities), and 57% (44/77 [5 without
information]) had no ID (Figure 2B). The fraction of sub-
jects with ID among carriers of pathogenic CNVs (42%)
was not significantly different from the fraction of ID
among all affected subjects (46%).
Inheritance data showed that 64% (54/84) of pathogenic
CNVs were de novo events (59% were deletions, and 41%
were duplications) and that the remaining (36%) were in-
herited, including seven X-linked CNVs maternally trans-
mitted to males and 23 (13 maternal and 10 paternal
[27%]) on autosomes (Figure 2C). Pathogenic deletions
tended to be smaller than duplications (Figure 2D). As ex-
pected, pathogenic de novo events were on average signif-
icantly larger than inherited ones (3.14 Mb—excluding
three affected subjects with whole-chromosome aneu-
ploidy—versus 1.44 Mb, respectively). We also observed
that the proportion of females was significantly increased
among carriers of highly penetrant pathogenic CNVs
(male-to-female ratio of 2:1 versus 6:1 among all affected
subjects; two-tailed Fisher’s exact test p¼ 0.017; Figure 2E).
In contrast, the male-to-female ratio among individuals
with CNVs associated with variable expressivity was 6:1.
Pathogenic CNVs included well-characterized highly
penetrant disorders associated with de novo CNVs, such
as Phelan-McDermid syndrome (MIM 606232, 22q13.3
deletion including SHANK3 [MIM 606230]), Smith-Mage-
nis syndrome (MIM 182290, 17p11.2 deletion includingated gene or overlapping at least 50% of the target loci were
selected for further analysis. Rare CNVs were divided into
three categories—pathogenic, uncertain clinical significance, or
benign—without regard to affected status.
(A) Percentage of individuals with CNVs overlapping genes and
loci implicated in ASD and/or ID (‘‘all CNV’’), pathogenic CNVs,
uncertain CNVs, or benign CNVs; and OR in affected and control
subjects.
(B) Percentage of individuals with pathogenic deletions or duplica-
tions and OR in affected and control subjects.
(C) Fraction of de novo CNVs in each category of affected subjects.
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Figure 2. All Pathogenic CNVs Identified in Affected Subjects
CNVs overlapping genes and loci implicated in ASD and/or ID in 2,446 affected subjects irrespective of ancestry, plus chromosomal ab-
normalities, other large rare de novo events, and further experimentally validated CNVs< 30 kb. Pathogenic CNVs identified in affected
subjects (84 CNVs in 82 probands) were divided into different categories: CNVs disrupting genes implicated in ASD and/or ID, genomic
disorders with recurrent breakpoints, genomic disorders with nonrecurrent breakpoints, chromosomal abnormalities, and other rare,
large de novo CNVs.
(A) Pie chart displaying the proportion for each of these categories. The number of events and inheritance are in parentheses.
(B) Percentage of probands with no ID or with nonsyndromic ASD among carriers of pathogenic CNVs.
(C) Distribution of de novo and inherited deletions and duplications in all CNVs versus in pathogenic CNVs in affected subjects.
(D) Size distribution of pathogenic CNVs.
(E) Gender distribution in all probands (n ¼ 2,446) versus in probands with autosomal pathogenic CNVs (n ¼ 72). Autosomal path-
ogenic CNVs were partitioned into two categories: highly penetrant CNVs (n ¼ 21) and pathogenic CNVs with variable expressivity
and/or incomplete penetrance (n ¼ 48). The male-to-female ratio is shown above each group. The number of affected subjects is
shown at the bottom of each bar. The proportion of females was increased among carriers of pathogenic CNVs associated with
high penetrance.
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RAI1 [MIM 607642]), Kleefstra syndrome (MIM 610253,
9q34.3 deletion including EHMT1 [MIM 607001]), Wil-
liams syndrome (MIM 194050, 7q11.23 deletion), and
large chromosomal abnormalities (Figure 2A; Table S7B).
Recurrent deleterious CNVs mediated by segmental dupli-
cations affecting 12 distinct regions were identified in
44 individuals. For example, two unrelated males were
found to harbor Xq28 duplications (MIM 300815), one
de novo and one maternal, corresponding to a ~0.3 Mb
segmental-duplication-mediated gain (153.2–153.5 Mb),
which was previously reported in X-linked ID.42 GDI1
(MIM 300104), mutations of which are linked to ID, is
the most likely gene involved (Figure S8). Thus, our find-
ings implicate abnormal GDI1 dosage in ASD. Interest-
ingly, one AGP proband with the duplication had autism
and a normal IQ, whereas the second had a borderline IQ
(72) (see Table S8 for phenotype information of all affected
subjects with pathogenic CNVs). Some other findings
include a 1.7 Mb de novo deletion encompassing ARID1B
(MIM 614556), recently implicated in ID and Coffin-Siris
syndrome (MIM 135900), and a small maternally inherited
intragenic deletion of HDAC4 (MIM 605314), involved
in brachydactyly-mental-retardation syndrome (MIM
600430; Figure S7). Although many 2q37 deletions have
been described in ASD, the deletion found in our proband
directly implicates HDAC4 haploinsufficiency in autism.
In Table S9, we analyzed data across three ASD cohorts,
including a total of 5,106 nonoverlapping affected subjects
and 3,512 control subjects from the AGP, the Simons
Simplex Collection, and the Autism Genetic Resource
Exchange (AGRE), for 17 loci andgenes commonly reported
as implicated in ASD. Themost frequent deletions involved
16p11.2 and NRXN1, accounting for 0.31% and 0.32% of
affected subjects, respectively. Typical 15q11–q13 duplica-
tions of the imprinted PWS-AS critical region were found
in 0.25% (13/5,106) of affected subjects, reaffirming this re-
gion’s importance in ASD. The majority of these duplica-
tions were of maternal origin, but two were paternally
derived (one without information; Table S9). Although
paternally derived duplications appear to have incomplete
penetrance in comparison to maternal ones, there have
been several cases reported in subjects with ASD.43
FMRP Targets, PSD Genes, and Other Neuronal Genes
Are Implicated in ASD
We expanded our analysis to lists of genes important for
neurological function, such as highly-brain-expressed
genes, PSD genes,33 genes implicated in neurological dis-
eases,44,45 genes with a high pHI,35 and FMRP targets,34
the latter of which have been reported to be enriched in
de novo LoF SNVs.7 Our analysis focused on exonic events,
and deletions and duplications were analyzed separately
(Figures 3A and 3B).
FMRP targets (n ¼ 842) and PSD genes (n ¼ 1,453) car-
ried a significant excess of both deletions and duplications
in affected subjects (Figures 3A and 3B). Five percent (73/
1,486) of affected subjects with exonic CNVs, including684 The American Journal of Human Genetics 94, 677–694, May 1, 252 subjects with genes not previously implicated in ASD
and/or ID, carried deletions overlapping one or more
FMRP targets, yielding 43 ASD candidate genes (Figure 3A;
Table S10). Given that the lists of FMRP targets and PSD
genes shared 279 genes, we performed conditional ana-
lyses showing that the excess of affected subjects carrying
deletions overlapping PSD genes was independent of the
signal in FMRP targets (OR ¼ 2.62, 95% CI ¼ 1.62–4.32,
p ¼ 2.24 3 105) and represented 4% of subjects with
exonic events (59/1,486) or 3% after exclusion of
pathogenic events (p¼ 0.007). Notably, females were over-
represented among affected subjects carrying exonic
deletions overlapping FMRP targets (17 females in 73
affected subjects, 1.98-fold more than males, p ¼ 0.022,
95% CI ¼ 1.06–3.52).
Brain-expressed genes showed significant excess in
affected versus control subjects for deletions only (OR ¼
1.89, 95% CI ¼ 1.51–2.37, Fisher’s exact test p ¼ 2.6 3
108; Figures 3A and 3B). Similarly, deletions (and not
duplications) overlapping genes implicated in dominant
neurological diseases and orthologous genes associated
with abnormal phenotypes in heterozygous knockout
mice conferred significant increase in ASD risk (OR ¼
2.94, 95% CI ¼ 1.76–4.93, p ¼ 2.5 3 105). Many of the
genes implicated in dominant diseases have been related
to loss of function or haploinsufficiency, previously sug-
gested to be more frequent and penetrant when deletions
rather than duplications are involved.46 Accordingly, we
detected an excess of affected subjects carrying deletions
overlapping genes with a high pHI (>0.35) (OR ¼ 1.41,
95% CI ¼ 1.13–1.76, p ¼ 0.002).
Increased Multigene Burden in ASD-Affected Subjects
We tested whether multiple genes within a CNV or across
unlinked genetic lesions in the same individual might act
in concert to increase risk of ASD. In logit modeling, the
number of genes overlapped by CNVs, the average brain-
expression value for those genes, and the deletion or dupli-
cation status were used as predictors with the case-control
status as the outcome (Figures 3C and 3D).
We found that ASD risk increased (as measured by the
predicted OR) as the numbers of deleted brain-expressed
genes increased (generalized linear model chi-square good-
ness of fit, p¼ 3.23 105 and p¼ 4.73 107, respectively;
Figures 3C and 3D). These results were consistent across
the various models tested (Tables S11A–S11E). There was
a decrease in signal after removal of affected subjects
with at least one de novo event, suggesting that most of
the risk can be attributed to de novo CNVs. Notably, the
signal further decreased 2-fold when the remaining patho-
genic CNVs were removed, confirming that pathogenic in-
herited CNVs alone also carry risk. Moreover, we found
that gene density contributed significantly to increased
risk only when de novo CNVs and inherited pathogenic
CNVs were considered, whereas a higher-than-average
level of gene expression in deletions (but not duplications)
was a contributor irrespective of CNV status (i.e., even after014
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Figure 3. Enrichment of Functional Gene Sets Affected by Rare Exonic CNVs in Affected versus Control Subjects
Overrepresentation of deletions (A) and duplications (B) in various functional gene sets. ORs, with 95% CIs, and the percentages of
affected subjects (n ¼ 1,486) and control subjects (n ¼ 1,820) with exonic CNVs overlapping genes are given for the following gene
sets: (1) highly-brain-expressed genes (log(RPKM) > 4.5, BrainSpan; n ¼ 5,610); (2) functionally characterized control genes not ex-
pressed in the brain (log(RPKM) < 1, BrainSpan; n ¼ 5,410); (3) PSD genes (n ¼ 1,453);33 (4) FMRP interactors (n ¼ 842);34 (5) genes
associated with neurological phenotypes compiled from the HPO andMPO (n¼ 3,112); (6) genes as described in (5) but filtered for auto-
somal-dominant genes (n ¼ 739); and (7) genes grouped by their pHI35 into three subgroups: pHI > 0.15 (n ¼ 8,862), pHI > 0.35 (n ¼
4,136,) and pHI > 0.55 (n ¼ 2,214). Genes with a pHI > 0.35 were considered haploinsufficient. The p values for affected and control
subjects were estimated with two-tailed Fisher’s exact tests (*p < 0.01, **p < 0.001, ***p < 0.0001).
(C–D) Pattern of increased burden as the number of brain-expressed genes affected by deletions (C) or duplications (D) increased. The
percentages of affected and control subjects with CNVs overlapping genes are shown for deletions and duplications separately. For esti-
mating the expected ORs (stars), a logit model of case status (affected or control) was fit to covariates, namely CNV status, the number of
genes covered by each CNV, and their average brain expression levels (neocortex, BrainSpan). See Tables S11A–S11E for the results of
alternative models, all of which showed that ASD risk increased as a function of the number of brain-expressed genes affected by a
CNV, even after within-subject dependency of CNVs was accounted for.removal of both de novo and inherited pathogenic CNVs)
(Tables S11A–S11E). Thus, it is likely that de novo and
pathogenic CNVs contribute to risk by altering the expres-
sion of more than one gene, suggesting that genetic inter-
actions between these genes can underlie ASD risk.
Network Analysis Links Exonic Deletions to
Neurodevelopmental Processes
We performed a gene-set enrichment analysis6 on our
expanded sample set after refining our criteria to consider
only exonic events (see Supplemental Data for details)
and found only deletions to be significantly enriched inThe Amgene sets in affected versus control subjects (Figure 4A).
We found 86 significantly enriched gene sets, including
MAPK signaling components and neuronal synaptic
functions and processes, in 42.5% (335/789) of affected
subjects with exonic deletions (Figure 4A; Tables S12A–
S12D). Enrichment of synaptic functioning has also been
reported among inherited events in the AGRE families47
and among de novo events in the Simons Simplex Collec-
tion.36 Enriched sets delineate candidate genes disrupted
by deletions not found in control subjects; these genes
notably include those in the KEGG glutamatergic pathway
(e.g., GRIK2 [MIM 138244], GRM5 [MIM 604102], SHANK1erican Journal of Human Genetics 94, 677–694, May 1, 2014 685
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Figure 4. Functional ASD Maps
(A) Gene-set enrichment for rare exonic deletions (de novo and inherited) in affected versus control subjects. Enrichment results were
mapped as a network of gene sets (nodes) related bymutual overlap (edges). Node size is proportional to the gene-set size, and edge thick-
ness scales with the number of genes overlapping between sets. Only gene sets enriched in affected subjects with a FDR % 20% are
(legend continued on next page)
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[MIM 604999], SHANK2 [MIM 603290], and SHANK3
[MIM 606230]; Figure S2A and Tables S13A–S13D), the
KEGG cholinergic pathway (e.g., KCNJ12 [MIM 602323],
CHAT [MIM 118490], and SLC18A3 [MIM 600336], the
latter two of which are within a recurrent 10q11.21–
q11.23 deletion, recently reported in individuals with
ID and ASD;48 Figure S2B and Tables S13A–S13D), or in
both pathways (e.g., GNG13 [MIM 607298], PRKACB
[MIM 176892], PLCB1 [MIM 607120], CAMK2G [MIM
602123 ], and PPP3CB [MIM 114106]). When analyzing
human homologs of mouse genes, we also found
enrichment of phenotypes mostly related to the brain,
including abnormal telencephalon morphology, neuron
morphology, behavior, and nervous system physiology
(Table S12D).
Genes within De Novo CNVs Cluster in a Gene
Network
De novo deletions (52 in European affected subjects) were
found to be significantly enriched within each gene set or
pathway cluster (for 85 of the 86 gene sets or pathways), as
well as across clusters (chi-square test p ¼ 9.8 3 109)
(Table S12B), prompting us to search for enriched biolog-
ical functions within de novo events separately. Taking
into account our observations of a significant multigene
burden in ASD subjects (Figures 3C and 3D), we analyzed
de novo events by using NETBAG36 to identify up to two
ASD candidate genes per CNV among 102 de novo events
in 99 subjects. NETBAG identifies networks of genes under
the premise that if genomic regions are perturbed by
genetic variants associated with the same phenotype,
they will contain genes forming connected clusters. The
NETBAG analysis resulted in a network of 113 genes
(global cluster p value ¼ 0.02; Figure 4B). Ten genes have
been previously implicated in autosomal-dominant or
X-linked forms of ASD and ID (UBE3A [MIM 601623],
NRXN1, SHANK2, EHMT1, SYNGAP1 [MIM 603384], and
SMARCA2 [MIM 600014]) or ID only (ZEB2 [MIM
605802], FLNA [MIM 300017], SKI [MIM 164780], and
IKBKG [MIM 300248]). On the basis of cumulative evi-
dence from various sources, an additional 68% (67/98)
are likely to affect ASD risk (Tables S14A–S14E); 27/67 of
these are either FMRP targets or PSD genes. Compared to
all other genes within de novo CNVs (or deletion CNVs
only), genes in the network exhibited a significantly
higher pHI (Wilcoxon rank sum p ¼ 7.07 3 108), and
55% (59/107 [6 without information]) had a pHI > 0.35.shown; gene sets are colored by different red intensity scales on the ba
whether the gene set is also enriched with genes known to cause ASD
labeled (groups are filled green or blue circles; subgroups are dashed
(B) Network of genes affected by rare de novo CNVs in affected subjec
CNVs (11 large de novo chromosome abnormalities were not conside
Nodes in the network correspond to genes, and edges correspond to i
to the overall cluster score. Edge widths are proportional to the prior l
genetic phenotype. Nodes are colored on the basis of whether gene
biased expression, in an analysis of 12 developmental stages of the B
logical functions (Tables S14A–S14E), and their colors represent func
The AmA similar NETBAG analysis of de novo CNVs in control
subjects did not yield significant results.36
We further characterized the biological processes related
to the NETBAG cluster (Tables S14B–S14E; Figures 4B and
S3) and found a significant enrichment (false-discovery
rate [FDR] < 10%) of genes involved in chromatin and
transcription regulation, MAPK signaling, and synaptic
signaling and components (Figure 4B). We recapitulated
many of the results of our gene-set analysis (Figure 4A),
notably for synapse functions and processes, and also iden-
tified genes involved in chromatin and transcription
regulation. The latter category included a high-risk gene
associated with ASD, the chromatin gene CHD2 (MIM
602119), which is affected by a de novo 83 kb deletion in
a male with ASD, mild ID, and dysmorphic features
including micrognathia and protruding ears. His ASD-
affected brother has mild ID, similar dysmorphic features,
and epilepsy with onset at age 9 years and carries the same
deletion, which removes the first six exons of CHD2.
Neither parent carries the deletion, suggesting germline
mosaicism (the deletion arose on the paternal chromo-
some). De novo SNVs in CHD2 have been reported in an
ASD subject and in several individuals with a broad
spectrum of neurodevelopmental disorders, including ID
and epileptic encephalopathy8,49,50 (Figure S6). Two other
genes in the chromodomain family have been linked to
neurodevelopmental disorders: CHD7 (MIM 608892) in
CHARGE syndrome (MIM 214800) and CHD8 (MIM
610528) in ASD. Another example is TRIP12 (MIM
604506), encoding an E3 ubiquitin ligase that can regulate
chromatin function to maintain genome integrity (Figure
S12). The chromatin and transcription module showed a
predominance of genes with a prenatally biased expression
profile (Figures 4B and S4).
De Novo CNVs and LoF SNVs Converge on Functional
Gene Networks
We expanded our analysis to genes altered by both our
de novo CNVs (Figure 5A) and de novo LoF SNVs compiled
from four exome sequencing studies in ASD.7–10 Eleven
genes affected by de novo CNVs (NRXN1, SHANK2,
ARID1B, RIMS1 [MIM 606629], TRIP12, SMARCC2
[MIM 601734], DLL1 [MIM 606582], TM4SF19, MLL3
[MIM 606833], PHF2 [MIM 604351], and CSTF2T [MIM
611968]) were found to be altered by de novo LoF SNVs
among autism cohorts, and three of them (NRXN1,
SHANK2, and RIMS1) were selected by NETBAG (Figure 4B).sis of their FDR. The node stroke color (orange or purple) indicates
and/or ID. Groups of functionally related gene sets are circled and
lines), and the functions of prominent clusters are shown.
ts. Shown are NETBAG results from the analysis of 102 rare de novo
red; Table S1C), representing 75 nonredundant genic CNV regions.
nteractions. Node sizes are proportional to the gene’s contribution
ikelihood that the two corresponding genes contribute to a shared
s show prenatal- or postnatal-biased brain expression, or have no
rainSpan data set (Figure S4). Shaded ovals represent enriched bio-
tional themes shared among Figures 4A, 4B, and 5B.
erican Journal of Human Genetics 94, 677–694, May 1, 2014 687
Chromatin modification & 
Transcription regulation
Neuronal development &
Axon guidance
MAPK & 
other signalling
113 genes dn CNV (NETBAG)
(64 used, 56.6%)
58 34
1
3 4
2
3
AFF2
DMD
MECP2
RIMS1
NRXN1
SHANK2
CHD8
ARID1B
DYRK1A
SCN2A
EHMT1
SYNGAP1
SMARCA2
42
4
122 genes LoF dn SNV
(41 used, 33.6%)
92 known ASD genes, dominant (AD or XLD) or XLR in males
(54 used, 58.7%)
31 genes LoF XL SNVs in males
(7 used, 22.6%)
A
B
ARHGDIA
FGFR2
ITGA5 ARHGAP32SPATA13
EPHB2 L1CAM
SYNCRIP
MAPK8
CRKL
PARD3
CACNA1B
CACNA1C
RIMS1
CDK2
SYNJ2
DLGAP2
CDKL5
NLGN4X
SNRPN
SHANK2
TSC2
TSC1
PTEN
RAB5A
TNK2
MCF2SNX9
OCRL
IL1RAPL1
SVIL
NLGN3
NRXN1TBR1
NRXN3
CASK
PTPRD
ANKRD11
IQGAP2
RAC3
CSDE1
PIK3CB
MAP2K1
PTPN11
HRAS
NF1
SYNGAP1
ABL1
BRAF
PLCB1
GRIN2B
RAP1GDS1KRAS
YWHAE
PARK2
AFF2
SPAST
DYRK1A
CUBN
SCN2A
LRP2
HAUS7
MED12
FMR1
CYFIP1
SH3GL3
NCKAP1
MED13L
RER1
LIMK1
ABCA1
CREBBP
MDM2
SYN1
FLNA
ETS1
RPS6KA3
MAPK3
CAMK2G
ANK2
KAT2BKLF13
TBP
SRCAP
NFIA
IKBKG
PPM1D
TBC1D23
PRKAB2
PHF8
SMC2
KDM6A
SETD2 ZNF292
KIAA0232
ATP1B1
BAZ1B
SMARCC2
VCP
SOD2 FTSJ1
PSMB1
SMARCA2NIPBL
UPF3B PSMC2
CDK4
SMC1A
ARID1B
PIR
ZMYND11
CHD2
CHD8
NFIX
DTNADMD
DRP2
EHMT1
BCL11A
MAX
STAU2
PAFAH1B1
DCXMAPK11
CBX4
DLL1TAOK2
MAPK7
CACNA1F
SREBF1
SHANK3
MEF2C
ESR2
MAPK12
DST
PPP3CB
TCF3
FOXG1
ATOH1
MECP2
GARNL1
CNOT3
PAX5
SMAD4
SKI
STXBP1
SCN1A
CUL3
CUL2BRWD1
ERCC6
Figure 5. Genes Affected by CNVs and SNVs Converge on Functional Gene Networks
(A) Venn diagram showing the overview of 151 genes resulting from a DAPPLE analysis of 336 unique genes. A similar diagram of
DAPPLE input genes is shown in Figure S5. For the DAPPLE analysis, we compiled the following lists of genes: (1) 113 genes identified
from our de novo CNVs by NETBAG; (2) 122 genes with de novo LoF SNVs from four published exome sequencing studies;7–10 (3) 31
genes with hemizygous LoF SNVs on the X chromosome of male ASD subjects and not observed in male control subjects;16 and (4) 92
ASD-implicated genes previously described as autosomal dominant, X-linked dominant, or X-linked recessive in males.18
(B) A DAPPLE network of 151 genes (Table S15) from the genes in (A) shows direct interactions between associated proteins according to
the InWeb database. Nodes represent genes and are colored according to gene-set membership depicted in (A): genes identified from our
(legend continued on next page)
688 The American Journal of Human Genetics 94, 677–694, May 1, 2014
Of the 11 genes, only TM4SF19 (3q29) belongs to a
known locus associated with a recurrent genomic disorder.
Despite the limited overlap observed among genes altered
by de novo CNVs and LoF SNVs, there is reinforcing
evidence of the role of NRXN1 and SHANK2 in ASD (Fig-
ure 5A). In addition, RIMS1, altered by both a de novo
duplication and a LoF SNV (Figure 5A) and encoding a
brain-specific synaptic Rab3a-binding protein, emerges as
an ASD candidate gene. RIMS1 has a regulatory role in syn-
aptic-vesicle exocytosis modulating synaptic transmission
and plasticity.51 Three other genes affected by de novo
CNVs (also picked by NETBAG)—CHD2, SYNGAP1, and
SYNCRIP—are also affected by LoF de novo SNVs in
ID,50,52 and two (SYNGAP1 and DPYD [MIM 612779]) are
altered in schizophrenia.53 CHD2 (discussed above) and
SYNGAP1 (encoding a Ras/Rap GTP-activating protein)
are both involved in autosomal-dominant ID, ASD, and
epilepsy.54
Under the assumption that different genes harboring
suspected causative mutations for the same disorder often
physically interact, we sought to evaluate protein-protein
interactions (PPIs) encoded by genes known to be impli-
cated in ASD and genes affected by rare CNVs or SNVs
(data drawn from our de novo CNVs and published
de novo ASD LoF SNVs; Figures 5A, 5B, and S5). The union
set of 336 unique genes (Table S15) analyzed by DAPPLE37
resulted in a network of direct PPIs encoded by 151 genes
(Figure 5A) from each of the three main lists: 54/92
(58.7%) genes involved in ASD, 64/113 (56.6%) de novo
CNV genes, and 41/122 (33.6%) de novo LoF SNV genes.
The number of direct PPIs was 1.5-fold higher than ex-
pected (p < 0.001, Figure 5B), suggesting that many of
the de novo CNV or SNV genes and ASD-implicated genes
function cooperatively. Overrepresentation analysis iden-
tified convergent functional themes related to neuronal
development and axon guidance, signaling pathways,
and chromatin and transcription regulation. Overall, these
findings are consistent among the three different types of
analyses shown in Figures 4A, 4B, and 5.
Although54geneswerepreviously implicated inASD, the
DAPPLE analysis singled out an additional 97 CNV or SNV
high-confidence candidate genes (Figure 5B; Table S16).
We found that compared to the 54 ASD-implicated genes,
the newly selected 97 CNVor SNV genes had a comparably
high pHI (median pHI¼ 0.58, Figure 6A). This is consistent
with the observation that ASD subjects havemore deletions
with haploinsufficient genes than do controls (Figure 6B).
Furthermore, similar to genes with known disease-causing
mutations (Figure 6C), those genes have high functional-
indispensability scores and a comparable high degree ofde novo CNVs by NETBAG (red nodes), genes affected by de novo L
genes affected by hemizygous LoF SNVs on the X chromosome ofmal
nodes). Other node colors (orange, purple, green, dark yellow, or da
represent significant direct protein-protein interactions (as defined by
Shaded ovals represent enriched biological functions common amo
functional themes shared among Figures 4A, 4B, and 5B.
The Amcentrality (i.e., high number of direct neighbors) and num-
ber of networks in which they are involved (Figures 6D and
6E). Compared to the genome average, they are also among
the top 75% of more-conserved genes (on the basis of
Genomic Evolutionary Rate Profiling scores and PhyloP)
and are highly expressed in the brain. Interestingly, 39 of
the 97 genes are either FMRP-related or PSD genes (of the
initial 151 genes identified byDAPPLE, 51 are FMRP interac-
tors and 24 are PSD genes). Thus, despite little overlap in
genes, the strong interconnectedness between the resulting
networks identifies pathways through which the effects of
distinct mutations might converge.Discussion
We used multiple approaches to prioritize key candidate
ASD-associated genes disrupted by CNVs and further iden-
tified biological relationships and common pathways
shared among those genes. Our data (1) confirm excess
burden of genome-wide rare genic CNVs in an indepen-
dent set of ASD subjects versus control subjects; (2) further
reveal an extreme degree of etiological heterogeneity (36
different genetic loci were found among 82 individuals
with pathogenic CNVs); (3) confirm the contribution of
de novo CNVs to the etiology of autism and highlight
the contribution of inherited pathogenic imbalances
(36%); (4) show an increased proportion of females among
carriers of highly penetrant pathogenic CNVs, as well as
among carriers of deletions affecting FMRP targets; (5)
show no significant difference in the frequency of de
novo CNVs between simplex and multiplex families; (6)
show that both deletions and duplications involving
FMRP targets and PSD genes increase ASD risk; (7) show
evidence of multigene contributions to ASD; (8) show
that ASD-associated deletions impair synapse function
and neurodevelopmental processes; (9) implicate chro-
matin and transcription regulation genes in ASD in a
network analysis of de novo CNVs; and (10) show that
genes affected by de novo CNVs and de novo LoF SNVs
converge on functional gene networks.
Importantly, when considering highly penetrant patho-
genic CNVs, we found a 2:1male-to-female ratio (deviating
from the overall ratio of 6:1 in the study sample). In
contrast, the ratio was unchanged among carriers of
CNVs characterized by variable expressivity and/or incom-
plete penetrance. Moreover, among affected subjects,
females were twice as likely as males to have exonic dele-
tions involving FMRP targets. Given the sex bias of ASD
toward males, it has been suggested that females requireoF SNVs from published exome sequencing studies (blue nodes),
es (white nodes), and genes known to be implicated in ASD (yellow
rk purple) correspond to genes present in two or more lists. Edges
a common interactor binding degree of 2) in the InWeb database.
ng 10% or more genes in the network, and their colors represent
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Figure 6. Functional Metrics for Various Gene Sets Derived from CNV and SNV Studies, as well as HI Scores for Genic Deletions
(A) Box plots of pHIs for various genes sets. Boxes correspond to the spread between the upper and lower quartiles; medians are indicated
by a solid horizontal line, and whiskers extend up to 1.53 the interquartile range. ‘‘Genome’’ indicates all 16,781 genes with an available
pHI from an imputed data set, excluding seed genes. Only genes implicated in dominant, recessive, or X-linked disorders with neuro-
logical phenotypes in the HPO database (‘‘HPO het,’’ ‘‘HPO hom,’’ ‘‘HPO X,’’ respectively) and mouse genes whose homozygous, hetero-
zygous, or X-linked knockout (‘‘MPO het,’’ ‘‘MPO hom,’’ ‘‘MPO X,’’ respectively) causes various abnormal phenotypes were considered.
(legend continued on next page)
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a higher genetic load to express ASD,56 and our founda-
tional data support this general hypothesis. This same phe-
nomenon has recently been shown for SHANK157 and the
16p13.11 CNV.58
We observed significant enrichment of both deletion
and duplication events overlapping FMRP and PSD targets,
indicating that altered dosage of these genes can underlie
ASD susceptibility. This is consistent with evidence that
FMRP targets belong to multiple signaling and intercon-
nected pathways such as PI3K-Akt-TSC-PTEN-mTOR and
PI3K-RAS-MAPK,59,60 which have been linked to ASD
through both underexpression and overexpression of
genes in these pathways. Although both deletions and
duplications can contribute to risk, we found that dele-
tions can have a stronger impact when highly-brain-
expressed genes, genes conferring dominant phenotypes
in humans and mice, or genes with a high pHI are consid-
ered. We also found that ASD risk increases as a function
of the number of brain-expressed genes affected by rare
de novo and pathogenic CNVs, consistent with an additive
model of risk underlying ASD etiology.
We developed an expanded and extensively intercon-
nected network of high-confidence ASD candidate genes
by integrating protein products from CNV and SNV genes
and ASD-implicated genes. Overall, these results demon-
strate that genes involved in ASD participate in a wide
array of processes, from neuronal development and axon
guidance to MAPK and other kinase signaling cascades
(including the PI3K-Akt-mTOR and PI3K-RAS-MAPK
pathways) to chromatin modification and transcription
regulation. An increasing number of genes involved in
chromatin structure and epigenetic regulation have been
implicated in a variety of developmental disorders.61 Other
chromatin regulator genes, such as MBD5 (MIM 611472)
and KMT2D (MIM 602113), have been implicated in IDThe median pHI for HPO het was selected as the threshold to differen
Genes implicated in ASD and ID were further annotated into d
abbreviations are as follows: dn, de novo; allg; all genes; DEL, deleti
de novo CNVs with up to one gene per each CNV region; ‘‘2g-NBG 11
per CNV (as depicted in Figure 4B); ‘‘2g-NBG DEL/disr 80g,’’ subset o
(no duplications were considered); ‘‘ASD (CompStudies) dn SNV 12
sequencing studies; ‘‘ID (CompStudies) dn SNV 32g,’’ 32 genes aff
‘‘SCZ (Xu2012) dn SNV 22g,’’ 22 genes affected by de novo Lo
(Lim2013) rec SNV 49g,’’ 49 genes affected by hemizygous LoF SNV
SNV 73g,’’ 73 genes hit by recessive SNVs in consanguineous ID-aff
genes; ‘‘336g minus 151g excluded 185g,’’ 185 genes not used by DA
network of Figure 5B; ‘‘DAPPLE minus 54 known genes 97g,’’ 97 gen
not including the 54 genes previously implicated in ASD (yellow n
be involved in ASD.
(B) LOD scores of the probability that at least one gene within a rare
and control subjects. Deletion-based LOD scores are plotted as a funct
affected and control subjects. The p value for the difference in the s
(C) Box plots with the distribution of predicted functional indispensa
genes, neutral genes, genes with knownmutations as listed in the Hum
which LoFmutations result in infertility or death before puberty]) and
by DAPPLE, 151 genes selected by DAPPLE, 54 known ASD-implicated
exclusion of the 54 ASD-implicated genes).
(D) Box plots with the distributions of degree centrality in Multinet5
(E) Box plots with the distributions of the number of networks in whi
(C) and (D).
The Amand ASD, highlighting the need to further study this
category of genes as ASD risk factors.
In addition to underlining important pathways, our
results highlight specific genes in ASD risk. Whereas the
majority of the 97 genes in the CNV or SNV network
(not including the genes already known to be involved
in ASD) most likely act via haploinsufficiency, a few are
affected by duplications. One example is the duplication
of PIK3CB (MIM 602925), which is likely to increase its
expression and thus lead to excessive phosphatidylinositol
3-kinase (PI3K) activity. PI3K, which is regulated by
FMRP,59 is elevated in FXS mouse knockouts,62,63 and
downregulation of this pathway has been shown to
have therapeutic effect in ASD and FXS mouse models.
RAC3 (MIM 602050), another example of a gene affected
by duplication, encodes a Rho family GTPase that en-
hances neuritogenesis and neurite branching when over-
expressed.64
Our findings implicate many ASD candidate genes
altered by de novo, inherited, or X-linked CNVs (e.g.,
SETD5,miR137, and HDAC9 [MIM 606543]; Supplemental
Data section ‘‘Highlighted Genes’’) or altered by both
de novo CNVs and LoF SNVs (e.g., RIMS1, TRIP12, and
DLL1; Figures 4B and 5). Taken together, our results suggest
that rare variants affecting ASD risk in the population
collectively encompass hundreds of genes. Despite this
heterogeneity, many genes converge in interconnected
functional modules, providing diagnostic and therapeutic
targets.Supplemental Data
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